Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants

Summary

First-in-human study to provide an assessment of the safety, tolerability, pharmacokinetics (PK), including food effects and a drug-drug interaction, and pharmacodynamics (PD) of OD-07656 after administration of ascending single and multiple oral doses to healthy male and female participants in view of treating inflammatory bowel disease (IBD) (including Crohn's disease and ulcerative colitis), Blau syndrome, and spondyloarthritis

Timeline

Start

2024-02-12

Primary completion

2024-11-25

Completion

2024-11-25

Drugs

Indications